Biologic Drugs in Development

Balancing Innovation Protection and Affordability

January 29, 2021

Although a necessity, companies must strike a critical balance between protecting innovations with IP and providing affordable access to medicines.

Boehringer Ingelheim and Enara Bio Partner on Cancer Immunotherapies

January 15, 2021

The collaboration will focus on up to three types of lung and gastrointestinal cancers.

Biopharma Gets Back to “New Normal” Business

January 02, 2021

After a hectic 2020, biopharma looks to deliver on COVID-19 vaccines and move other promising therapies forward.

Lonza to Manufacture AstraZeneca's COVID-19 Long-Acting Antibody Combination

November 03, 2020

The agreement will provide capacity for the manufacturing of AZD7442, currently being developed for the potential prevention and treatment of COVID-19, at Lonza's Portsmouth, NH site.

Complex Manufacturing Processes Prompt New Inspection Methods

November 01, 2020

Complex manufacturing processes pose challenges for final product inspection needed to ensure product integrity at commercial launch.

Bio/Pharma Industry Works Overtime to Find COVID-19 Therapies

October 16, 2020

Bio/Pharma companies are galvanized to develop COVID-19 therapies under FDA’s acceleration program.

Orgenesis to Acquire Koligo Therapeutics

October 01, 2020

The acquisition will support the accelerated commercialization of Kyslecel (autologous pancreatic islets), Koligo’s personalized cell therapy for treating pancreatitis.

Lonza, Humanigen Partner to Expand Manufacturing of Lenzilumab for Potential COVID-19 Therapy

September 18, 2020

The collaboration will expand the manufacturing capacity for lenzilumab, a COVID-19 therapeutic candidate, in advance of a potential Emergency Use Authorization in 2020.

Novavax in COVID-19 Vaccine Manufacturing Agreement with Serum Institute of India

September 18, 2020

The agreement will Increase global manufacturing capacity for Novavax’s vaccine candidate, NVX-CoV2373, to more than two-billion annualized doses when at full capacity in 2021.

Lilly and Amgen in Manufacturing Collaboration for COVID-19 Antibody Therapies

September 18, 2020

The agreement between the two companies will significantly increase global supply capacity for Lilly's potential COVID-19 treatments.